[1] FDA. LYNPARZA[EB/OL].[2014-12-19](2015-02-02).http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl. pdf.
[2] Althaus FR,Richter C. ADP-ribosylation of proteins: enzymology and biological significance[J].Mol Biol Biochem Biophys,1987,37(1):1-237.
[3] Domchek SM,Weber BL.Clinical management of BRCA1 and BRCA2 mutation carriers[J]. Oncogene, 2006, 25(43):5825-5831.
[4] Moynahan ME,Chiu JW, Koller BH, et al. BRCA1 controls homology-directed DNA repair[J]. Mol Cell, 1999,4(4):511-518.
[5] Tutt A, Bertwistle D, Valentine J, et al. Mutation in BRCA2 stimulates crror-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequenced[J]. EMBO J,2001,20(17):4704-4716.
[6] Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J]. Nature, 2005, 434(7035):917-921.
[7] Bundred N, Gardovskis J, Jaskiewicz J,et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery[J]. Invest New Drugs, 2013, 31 (4): 949-958,
[8] Norris RE, Adamson PC, Nguyen VT,et al. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors[J]. Pediatr Blood Cancer, 2014 61 (1): 145-150.
[9] Sakai W, Swisher EM, Jacquemont C, et al. Functional restration of BRCA2 protein by secondary BRCA2-mutantedovarian carcinoma[J]. Cancer Res, 2009, 69(16):6381-6386.
[10] Gilabert M, Launay S, Ginestier C, et al. Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib[J]. PLoS One, 2014,9 (8): e104302.